Published in J Clin Oncol on January 01, 1999
Guidelines for the management of soft tissue sarcomas. Sarcoma (2010) 2.55
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol (2015) 2.19
Results of hepatic resection for sarcoma metastatic to liver. Ann Surg (2001) 1.75
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer (2014) 1.43
Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg (2016) 1.41
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol (2014) 1.17
Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer (2011) 1.14
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A (2008) 1.14
Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom. Sarcoma (2007) 1.13
Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma (2000) 1.12
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
Radiation-induced sarcoma of the breast: a systematic review. Oncologist (2012) 1.05
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer (2015) 1.04
Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma (2009) 1.01
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer (2011) 0.95
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer (2013) 0.95
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs (2009) 0.94
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer (2013) 0.93
Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis. World J Gastroenterol (2006) 0.91
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One (2012) 0.90
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett (2013) 0.89
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma (2010) 0.88
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma (2014) 0.88
Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol (2006) 0.87
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Laryngeal dedifferentiated liposarcoma. Eur Arch Otorhinolaryngol (2010) 0.86
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma (2006) 0.86
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs (2006) 0.84
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs (2009) 0.84
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma (2013) 0.83
Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report. J Med Case Rep (2012) 0.83
Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience. HPB (Oxford) (2007) 0.82
Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas. Clin Sarcoma Res (2014) 0.82
Oncological outcome and prognostic factors in the therapy of soft tissue sarcoma of the extremities. Orthop Rev (Pavia) (2012) 0.82
Sarcoma immunotherapy: past approaches and future directions. Sarcoma (2014) 0.81
Long-term survival of a patient with scalp angiosarcoma and multiple metastases treated using combination therapy: A case report. Oncol Lett (2015) 0.81
Primary Mediastinal Synovial Sarcoma Presenting as Superior Vena Cava Syndrome: A Rare Case Report and Review of the Literature. Case Rep Oncol Med (2015) 0.81
Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol Oncol (2014) 0.80
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer (2004) 0.80
Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. Cancer Imaging (2008) 0.80
Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. Int Semin Surg Oncol (2005) 0.80
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer (2015) 0.80
Management of advanced adult soft tissue sarcoma. Sarcoma (2003) 0.79
Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma (2013) 0.79
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Mar Drugs (2015) 0.79
Recent advances in understanding and managing leiomyosarcomas. F1000Prime Rep (2015) 0.79
High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre. Sarcoma (2004) 0.78
Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer (2008) 0.77
A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). Sarcoma (2004) 0.77
Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. Onco Targets Ther (2012) 0.77
A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). Sarcoma (2002) 0.77
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer (2006) 0.77
[Primary sarcomas and sarcoma metastases in the liver: morphological and molecular aspects]. Pathologe (2006) 0.76
Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. Anticancer Drugs (2016) 0.76
Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group. Sarcoma (2003) 0.76
UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res (2016) 0.75
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol (2015) 0.75
CTOS Board of Directors 1999-2000. Sarcoma (2001) 0.75
Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med (2016) 0.75
Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy. Breast Care (Basel) (2012) 0.75
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma (2016) 0.75
Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag (2016) 0.75
Orbital metastasis: a rare manifestation of scapular bone osteosarcoma. J Ophthalmic Vis Res (2015) 0.75
Challenges in the Surgical Treatment of Retroperitoneal Sarcomas. Indian J Surg (2015) 0.75
Primary Splenic Angiosarcoma Presenting as Idiopathic Thrombocytopenic Purpura: A Case Report and Review of the Literature. Case Rep Surg (2016) 0.75
Treating the Critically Ill with Radiotherapy: Lessons Learned from a Young Woman with Cardiac Angiosarcoma. Front Oncol (2017) 0.75
An unresectable retroperitoneal malignant fibrous histiocytoma: A case report. Oncol Lett (2016) 0.75
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clin Sarcoma Res (2015) 0.75
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med (2017) 0.75
The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB. Br J Cancer (2011) 0.75
Immunotherapies in sarcoma: Updates and future perspectives. World J Clin Oncol (2017) 0.75
Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. PLoS One (2016) 0.75
Trabectedin for advanced soft tissue sarcomas: optimizing use. Ther Clin Risk Manag (2014) 0.75
Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget (2017) 0.75
A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma. Sarcoma (2006) 0.75
Leiomyosarcoma: Principles of management. Intractable Rare Dis Res (2013) 0.75
Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. Onco Targets Ther (2017) 0.75
The value of trabectedin in the treatment of soft tissue sarcoma. Ther Clin Risk Manag (2016) 0.75
Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res (2016) 0.75
Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. BMC Cancer (2016) 0.75
Synchronous coexistence of liver metastases from cecal leiomyosarcoma and rectal adenocarcinoma: A case report. World J Gastroenterol (2017) 0.75
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol (2014) 0.75
Soft tissue and bone sarcoma group, 25th anniversary meeting on sarcomas, april 5-7, 2001, aarhus, denmark. Sarcoma (2001) 0.75
Notch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma. Sarcoma (2016) 0.75
Experiences with surgically treated primary or secondary hepatic sarcoma. Langenbecks Arch Surg (2017) 0.75
Surgery for liver metastases originating from sarcoma-case series. Langenbecks Arch Surg (2011) 0.75
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma. Oncotarget (2017) 0.75
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 5.71
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res (1994) 3.20
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol (1992) 2.91
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol (2000) 2.71
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
Tamoxifen in advanced breast cancer. Cancer Treat Rev (1978) 2.53
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer (1988) 2.46
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol (1990) 2.43
Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol (2003) 2.42
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 2.40
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst (1995) 2.35
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2008) 2.28
Lymphoid cellular responses in the blood after immunization in man. J Exp Med (1969) 2.25
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol (1992) 2.14
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol (2007) 2.11
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Six cases of gamma-D myelomatosis. Lancet (1966) 1.92
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol (1993) 1.91
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
The recognition of psychiatric morbidity on a medical oncology ward. J Psychosom Res (1989) 1.84
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol (2009) 1.81
Systematic review and meta-analysis of randomized clinical trials comparing single-incision versus conventional laparoscopic cholecystectomy. Br J Surg (2012) 1.80
Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J Clin Microbiol (2008) 1.80
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol (1992) 1.79
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 1.78
Multiple intracranial meningiomas. J Neurosurg (1989) 1.78
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet (1984) 1.77
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Drugs ten years later: epirubicin. Ann Oncol (1993) 1.74
The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol (1988) 1.73
Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci U S A (1990) 1.72
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
Identical reactivity of monoclonal antibodies HNK-1 and NC-1: conservation in vertebrates on cells derived from the neural primordium and on some leukocytes. Cell Differ (1984) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol (1997) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61